Filing Flows › Cryoport (CYRX) › Q3 2026 › vs Q2 2026
Cryoport (CYRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Cryoport's revenue rose $1.2M (+3%) from $49.0M in Q2 2026 to $50.2M in Q3 2026. The biggest changes: Product +$654K (+3%); Service +$595K (+2%).
Cryoport, Q3 2026: revenue $50.2M (+14% year over year), operating margin -17.5%, net loss $10.9M, operating cash flow $5.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| BioLogistics Solutions | $22.5M | $22.4M | $163K | +0.7% |
| BioStorage/BioServices | $6.0M | $5.6M | $432K | +8% |
| Service | $28.6M | $28.0M | $595K | +2% |
| Product | $21.7M | $21.0M | $654K | +3% |
| Revenue | $50.2M | $49.0M | $1.2M | +3% |
| Net loss | $10.9M | $8.3M | $2.6M | +31% |
| Costs & expenses | $61.1M | $59.5M | $1.6M | +3% |
| Operating costs | $59.0M | $59.0M | $14K | 0% |
| Interest & other, net | $1.9M | −$2.3M | $4.1M | — |
| Income tax | $194K | $505K | −$311K | -62% |
| Cost of revenue | $26.4M | $26.1M | $239K | +0.9% |
| Research & development | $4.7M | $4.9M | −$118K | -2% |
| SG&A | $27.9M | $28.0M | −$107K | -0.4% |
| Operating cash sources | $16.1M | $9.4M | $6.7M | +71% |
| Depreciation & amortization | $6.5M | $6.6M | −$122K | -2% |
| Share-based compensation | $2.3M | $2.4M | −$56K | -2% |
| Working capital & other | $7.3M | $395K | $6.9M | 18× |
| Net loss absorbed | $10.9M | $8.3M | $2.6M | +31% |
| Operating cash flow | $5.2M | $1.1M | $4.1M | +361% |
| Capital expenditures | $5.3M | $9.1M | −$3.8M | -42% |
| Negative free cash flow (OCF − capex) | $40K | $8.0M | −$7.9M | -99% |
Questions
How much did Cryoport's revenue grow quarter over quarter in Q3 2026?
Cryoport's revenue rose $1.2M (+3%) from $49.0M in Q2 2026 to $50.2M in Q3 2026.
What drove Cryoport's revenue change in Q3 2026?
Product +$654K (+3%); Service +$595K (+2%).